Cargando…
Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors
BACKGROUND. In postmenopausal women diagnosed with breast cancer (BC), most BC tumors are hormone receptor positive and guidelines recommend adjuvant endocrine therapy that includes an aromatase inhibitor (AI). This study investigates the impact of a 6‐week, home‐based, self‐directed walking program...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634775/ https://www.ncbi.nlm.nih.gov/pubmed/28698390 http://dx.doi.org/10.1634/theoncologist.2017-0174 |
_version_ | 1783270159037759488 |
---|---|
author | Nyrop, Kirsten A. Callahan, Leigh F. Cleveland, Rebecca J. Arbeeva, Liubov L. Hackney, Betsy S. Muss, Hyman B. |
author_facet | Nyrop, Kirsten A. Callahan, Leigh F. Cleveland, Rebecca J. Arbeeva, Liubov L. Hackney, Betsy S. Muss, Hyman B. |
author_sort | Nyrop, Kirsten A. |
collection | PubMed |
description | BACKGROUND. In postmenopausal women diagnosed with breast cancer (BC), most BC tumors are hormone receptor positive and guidelines recommend adjuvant endocrine therapy that includes an aromatase inhibitor (AI). This study investigates the impact of a 6‐week, home‐based, self‐directed walking program on the commonly reported side effect of AI‐associated arthralgia (AIAA). MATERIALS AND METHODS. In this phase II trial, consented BC patients were randomized to walking Intervention (n = 31) or Wait List Control (WLC; n = 31). Eligibility criteria included: stage 0–III BC, on AI for at least 4 weeks, ≥3 on a 5‐point scale inquiring about joint symptom intensity “at its worst,” and exercising ≤150 minutes per week. Outcomes were self‐reported joint symptoms and psychosocial measures. Analyses comparing Intervention and WLC groups were conducted on an intention‐to‐treat basis to assess intervention impact at 6 weeks (postintervention) and at 6‐months follow‐up. Adjusted means were calculated to assess differences in two groups. RESULTS. In our final sample (n = 62), mean age was 64 years, 74% were white, and 63% had a body mass index of 30 or higher. At postintervention, Intervention group participants reported significantly increased walking minutes per week, reduced stiffness, less difficulty with activities of daily living (ADL), and less perceived helplessness in managing joint symptoms. At 6‐months follow‐up (postwalking period in both Intervention and WLC), walking minutes per week had decreased significantly; however, improvements in stiffness and difficulty with ADLs were maintained. CONCLUSION. This study adds to the growing evidence base suggesting exercise as a safe alternative or adjunct to medications for the management of AIAA. IMPLICATIONS FOR PRACTICE. Breast cancer survivors whose adjuvant endocrine treatment includes an aromatase inhibitor (AI) often experience the side effect of AI‐associated arthralgia (AIAA). This study investigates the impact of a 6‐week, home‐based, self‐directed walking program in the management of AIAA. Compared with Wait List Control, women in the Intervention group reported significantly increased walking minutes per week, reduced stiffness, less difficulty with activities of daily living, and less perceived helplessness in managing joint symptoms. This study adds to the growing evidence base suggesting exercise as a safe alternative or adjunct to medications for the management of AIAA. |
format | Online Article Text |
id | pubmed-5634775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | AlphaMed Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56347752018-04-01 Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors Nyrop, Kirsten A. Callahan, Leigh F. Cleveland, Rebecca J. Arbeeva, Liubov L. Hackney, Betsy S. Muss, Hyman B. Oncologist Breast Cancer BACKGROUND. In postmenopausal women diagnosed with breast cancer (BC), most BC tumors are hormone receptor positive and guidelines recommend adjuvant endocrine therapy that includes an aromatase inhibitor (AI). This study investigates the impact of a 6‐week, home‐based, self‐directed walking program on the commonly reported side effect of AI‐associated arthralgia (AIAA). MATERIALS AND METHODS. In this phase II trial, consented BC patients were randomized to walking Intervention (n = 31) or Wait List Control (WLC; n = 31). Eligibility criteria included: stage 0–III BC, on AI for at least 4 weeks, ≥3 on a 5‐point scale inquiring about joint symptom intensity “at its worst,” and exercising ≤150 minutes per week. Outcomes were self‐reported joint symptoms and psychosocial measures. Analyses comparing Intervention and WLC groups were conducted on an intention‐to‐treat basis to assess intervention impact at 6 weeks (postintervention) and at 6‐months follow‐up. Adjusted means were calculated to assess differences in two groups. RESULTS. In our final sample (n = 62), mean age was 64 years, 74% were white, and 63% had a body mass index of 30 or higher. At postintervention, Intervention group participants reported significantly increased walking minutes per week, reduced stiffness, less difficulty with activities of daily living (ADL), and less perceived helplessness in managing joint symptoms. At 6‐months follow‐up (postwalking period in both Intervention and WLC), walking minutes per week had decreased significantly; however, improvements in stiffness and difficulty with ADLs were maintained. CONCLUSION. This study adds to the growing evidence base suggesting exercise as a safe alternative or adjunct to medications for the management of AIAA. IMPLICATIONS FOR PRACTICE. Breast cancer survivors whose adjuvant endocrine treatment includes an aromatase inhibitor (AI) often experience the side effect of AI‐associated arthralgia (AIAA). This study investigates the impact of a 6‐week, home‐based, self‐directed walking program in the management of AIAA. Compared with Wait List Control, women in the Intervention group reported significantly increased walking minutes per week, reduced stiffness, less difficulty with activities of daily living, and less perceived helplessness in managing joint symptoms. This study adds to the growing evidence base suggesting exercise as a safe alternative or adjunct to medications for the management of AIAA. AlphaMed Press 2017-07-11 2017-10 /pmc/articles/PMC5634775/ /pubmed/28698390 http://dx.doi.org/10.1634/theoncologist.2017-0174 Text en © AlphaMed Press 2017 |
spellingShingle | Breast Cancer Nyrop, Kirsten A. Callahan, Leigh F. Cleveland, Rebecca J. Arbeeva, Liubov L. Hackney, Betsy S. Muss, Hyman B. Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors |
title | Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors |
title_full | Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors |
title_fullStr | Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors |
title_full_unstemmed | Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors |
title_short | Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors |
title_sort | randomized controlled trial of a home‐based walking program to reduce moderate to severe aromatase inhibitor‐associated arthralgia in breast cancer survivors |
topic | Breast Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634775/ https://www.ncbi.nlm.nih.gov/pubmed/28698390 http://dx.doi.org/10.1634/theoncologist.2017-0174 |
work_keys_str_mv | AT nyropkirstena randomizedcontrolledtrialofahomebasedwalkingprogramtoreducemoderatetoseverearomataseinhibitorassociatedarthralgiainbreastcancersurvivors AT callahanleighf randomizedcontrolledtrialofahomebasedwalkingprogramtoreducemoderatetoseverearomataseinhibitorassociatedarthralgiainbreastcancersurvivors AT clevelandrebeccaj randomizedcontrolledtrialofahomebasedwalkingprogramtoreducemoderatetoseverearomataseinhibitorassociatedarthralgiainbreastcancersurvivors AT arbeevaliubovl randomizedcontrolledtrialofahomebasedwalkingprogramtoreducemoderatetoseverearomataseinhibitorassociatedarthralgiainbreastcancersurvivors AT hackneybetsys randomizedcontrolledtrialofahomebasedwalkingprogramtoreducemoderatetoseverearomataseinhibitorassociatedarthralgiainbreastcancersurvivors AT musshymanb randomizedcontrolledtrialofahomebasedwalkingprogramtoreducemoderatetoseverearomataseinhibitorassociatedarthralgiainbreastcancersurvivors |